Want to see WST full AI Analyst Report?
WST Stock Chart & Stats
$328.20
-$27.28(-7.67%)
At close: 4:00 PM EDT
$328.20
-$27.28(-7.67%)
Day’s Range― - ―
52-Week Range$223.83 - $386.00
Previous CloseN/A
Volume1.51M
Average Volume (3M)811.59K
Market Cap
$24.85B
Enterprise Value$25.48K
Total Cash (Recent Filing)$435.80M
Total Debt (Recent Filing)$312.10M
Price to Earnings (P/E)44.9
Beta0.78
Next Earnings
Oct 22, 2026EPS Estimate
2.19Next Dividend Ex-DateN/A
Dividend Yield0.25%
Share Statistics
EPS (TTM)7.87
Shares Outstanding70,375,760
10 Day Avg. Volume864,114
30 Day Avg. Volume811,594
Financial Highlights & Ratios
PEG Ratio33.99
Price to Book (P/B)6.26
Price to Sales (P/S)6.47
P/FCF Ratio42.42
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$403.78Price Target Upside23.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)8.97
Revenue Forecast (FY)$3.37B
Bulls Say, Bears Say
Bulls Say
High-value Biologics And GLP-1 GrowthStrong demand for biologics, GLP-1 therapies and advanced delivery devices is shifting revenue toward differentiated products. These regulated, qualified components can support recurring volume growth and strengthen West’s position in expanding injectable-drug markets.
Healthy Margins With Expansion PotentialThe mix shift toward high-value components and delivery devices is producing meaningful operating leverage. If biologics and HVP growth persists, the improved mix should support more durable profitability than reliance on lower-value Standard Products.
Low Leverage And Strategic Technology AccessMinimal leverage preserves financial flexibility for investment and shareholder returns. The extended Daikyo relationship also maintains access to complementary technology and international distribution, reinforcing West’s capabilities in regulated pharmaceutical packaging.
Bears Say
Free Cash Flow Below EarningsAlthough operating cash flow remains solid, weaker free cash flow conversion indicates that working capital or investment is absorbing more cash. Persistent conversion pressure could limit funding available for capacity expansion, acquisitions and shareholder returns.
Modest Underlying Growth And Margin NormalizationRecent acceleration is encouraging, but the broader earnings base still reflects modest top-line growth and profitability below prior peaks. This suggests that mix, inflation or other operating pressures may constrain how much of the current margin improvement persists.
West Vantage Transition RiskThe contract exit creates a defined revenue headwind and may leave West Vantage weaker before drug-handling activity improves. This transition could offset strength in HVP businesses and make consolidated growth and operating execution less predictable over coming quarters.
West Pharmaceutical Services News
WST FAQ
What was West Pharmaceutical Services, Inc.’s price range in the past 12 months?
West Pharmaceutical Services, Inc. lowest stock price was $223.83 and its highest was $386.00 in the past 12 months.
What is West Pharmaceutical Services, Inc.’s market cap?
West Pharmaceutical Services, Inc.’s market cap is $24.85B.
When is West Pharmaceutical Services, Inc.’s upcoming earnings report date?
West Pharmaceutical Services, Inc.’s upcoming earnings report date is Oct 22, 2026 which is in 60 days.
How were West Pharmaceutical Services, Inc.’s earnings last quarter?
West Pharmaceutical Services, Inc. released its earnings results on Jul 23, 2026. The company reported $2.37 earnings per share for the quarter, beating the consensus estimate of $2.082 by $0.288.
Is West Pharmaceutical Services, Inc. overvalued?
According to Wall Street analysts West Pharmaceutical Services, Inc.’s price is currently Undervalued.
Does West Pharmaceutical Services, Inc. pay dividends?
West Pharmaceutical Services, Inc. pays a Quarterly dividend of $0.22 which represents an annual dividend yield of 0.25%. See more information on West Pharmaceutical Services, Inc. dividends here
What is West Pharmaceutical Services, Inc.’s EPS estimate?
West Pharmaceutical Services, Inc.’s EPS estimate is 2.19.
How many shares outstanding does West Pharmaceutical Services, Inc. have?
West Pharmaceutical Services, Inc. has 70,375,760 shares outstanding.
What happened to West Pharmaceutical Services, Inc.’s price movement after its last earnings report?
West Pharmaceutical Services, Inc. reported an EPS of $2.37 in its last earnings report, beating expectations of $2.082. Following the earnings report the stock price went down -0.818%.
Which hedge fund is a major shareholder of West Pharmaceutical Services, Inc.?
Currently, no hedge funds are holding shares in WST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
West Pharmaceutical Services Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$403.78 (23.03% Upside)
$403.78 (23.03% Upside)
Blogger Sentiment
Bullish
WST Sentiment 82%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 863.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.98%
12-Months-Change
Fundamentals
Return on Equity
0.25%
Trailing 12-Months
Asset Growth
3.13%
Trailing 12-Months
Company Description
West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
WST Company Deck
WST Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive: the company reported a clear top‑ and bottom‑line beat, raised full‑year guidance, and demonstrated margin expansion driven by a favorable mix toward high‑value HVP Components, Biologics and Delivery Devices. Management highlighted operational resilience after a cyber incident, strong growth in Asia Pacific, and continued capital returns. Near‑term headwinds include the cyber incident's effect on West Vantage (pushing revenue into later quarters), operating cash‑flow timing pressure, inflationary costs and FX exposure, and the comparability impact from the SmartDose 3.5 divestiture. Overall, the upside from high‑value product mix, margin gains and raised guidance meaningfully outweigh the discrete and manageable lowlights.View all WST earnings summariesWST Revenue Breakdown
81.07% Proprietary Products
18.93% Contract-Manufactured Products
0.00% Intersegment sales elimination
WST Stock 12 Month Forecast
Average Price Target
$403.78
▲(23.03% Upside)
Technical Analysis
Ownership Overview
0.56% Insiders
26.53% Mutual Funds
27.42% Other Institutional Investors
16.10% Public Companies and
Individual Investors